Asparkam-L, 45.2mg/ml+40 mg/ml 5 ml 10 pcs

The mechanism of action of Asparkam is related to effective participation of L-asparaginate in transport of magnesium and potassium ions into intracellular space.Magnesium activates sodium-potassium-ATPase, removing sodium ions from cell and returning potassium ions; reduces sodium concentration and prevents its exchange for calcium in vascular smooth muscles, reducing their resistance. Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine, etc.

The two ions support the polarization of cell membranes.

The drug regulates the conduction of impulses along the nerve fibers, synaptic transmission, muscle contraction, and the work of the heart muscle. Due to magnesium ions the product participates in the processes of energy input and output, normalizes membrane permeability, neuromuscular conduction, DNA and RNA synthesis, cell growth, cell division, oxygen assimilation and phosphate synthesis.

Indications

Active ingredient

Composition

1 ml of solution for intravenous administration contains:

acting substances:

Magnesium asparaginate anhydrous 40 mg (magnesium content – 3.37 mg),

Potassium asparaginate anhydrous 45.2 mg (potassium content 10.33 mg);

excipients:

sorbitol (sorbitol),

water for injection.

How to take, the dosage

The drug is administered intravenously (by drip or stream). The dose of the drug is determined individually depending on the indications for use.

Intravenously by drop infusion at a rate of 25 drops per 1 minute 1 to 2 times a day of 10-20 ml (1-2 ampoules of 10 ml or 2-4 ampoules of 5 ml) diluted in 100-200 ml of sodium chloride isotonic solution or 5% glucose solution.

In case of jet injection the contents of 1 ampoule of 10 ml or 2 ampoules of 5 ml are diluted in 20 ml of sterile water for injection or 5% glucose solution and injected slowly (not more than 5 ml per minute) into a vein.

Interaction

Potassium-saving diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs – risk of hyperkalemia up to the development of arrhythmia and asystole.

Manages hypokalemia caused by glucocorticosteroids.

Reduces unwanted effects of cardiac glycosides.

Due to the content of magnesium ions it reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

Anesthetics increase the suppressive effect of magnesium on the central nervous system.

May increase neuromuscular blockade caused by depolarizing myorelaxants (atracurium besylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide).

Calcitriol increases the concentration of magnesium in the blood plasma, calcium preparations reduce the effect of magnesium.

The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerability).

Special Instructions

There have been no studies to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Overdose

Symptoms: hyperkalemia and hypermagnesemia.

Treatment: intravenous calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

Similarities